NIH R01 · 2024
Potent broadly neutralizing antibody development against the HIV-1 fusion peptide epitope
Project Summary/Abstract Vaccines and antibody interventions against human immunodeficiency virus-1 (HIV-1) have made tremendous progress, but are not yet ready for broad clinical use. A vaccine that prevents new infections could provide a major boost to ending the HIV-1 pandemic by blocking transmissions. The HIV-1 fusion peptide (FP) has shown promise as a broadly neutralizing antibody (bNAb)-directed vaccine target site because vaccine antigens can effectively prime and expand B cell responses targeting FP. However, HIV-1 genetic diversity at FP and the limited potency & neutralization breadth of known antibodies at the FP site has slowed progress for FP-directed interventions. A better…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.